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Ferulic acid ethyl esterOxidative stress is involved in the onset, progression and pathogenesis of a number of diseases including neu-
rodegenerative diseases. It is critical to develop a pharmacological approach to combat oxidative stress which
may reduce the risk of diseases and help in promoting healthy life. In an attempt to reduce the side effects
associated with allopathic medicines a number of studies are now focusing on developing treatment regi-
mens from naturally occurring plant products. In this review, the protective role of ferulic acid (4-hydroxy-
3-methoxycinnamic acid) (FA), a naturally occurring antioxidant compound found in fruit, some vegetables,
and grains, and its ethyl ester derivative are discussed with respect to neurodegeneration. This article is part
of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Under physiological conditions there is always a balance between
the amounts of reactive oxygen species (ROS) or reactive nitrogen
species (RNS) that are generated, and the antioxidant enzymes or
molecules designed to modulate these free radicals. However, due
to certain not well understood processes this balance sometimes is
lost favoring increased production of ROS/RNS. This increase in the
levels of ROS/RNS is detrimental to normal cellular function. The ac-
cumulation of ROS/RNS and associated damage is referred to as oxida-
tive stress/nitrosative stress.
ROS/RNS are generated by various ways, such as irradiation by UV
light/X-rays/gamma-rays, metal-catalyzed reactions (iron and hydrogen
peroxide forming hydroxyl radicals), inﬂammation, mitochondrial elec-
tron transport chain and othermechanisms. In a number of neurodegen-
erative diseases involving different protein aggregates such as senile
plaques (the main component in senile plaque is amyloid beta-
peptide) in Alzheimer's disease (AD), Lewy body (alpha synuclein is
the main component) in Parkinson disease (PD), etc., increased levels
of ROS/RNSwere found, suggesting a relation of free radicals in the path-
ogenesis of these diseases. Regulated levels of ROS/RNS are important in
controlling biological systems such as defense against infectious agents,
and in the function of a number of cellular signaling systems. For exam-
ple, nitric oxide (NO•) plays an important role in regulatingants and Antioxidant Treatment
l rights reserved.neurotransmission, defense mechanisms, smooth muscle relaxation
and immune regulation [1–4].
Increased levels of ROS/RNS can damage biomolecules such as
proteins, lipids, carbohydrates and nucleic acid. In case of proteins
ROS/RNS can introduce a variety of modiﬁcations in amino acid resi-
dues, including, among others, cysteine, methionine, tryptophan, ar-
ginine, lysine, proline, and histidine [5–8]. Most frequently studied
modiﬁcations by ROS/RNS include protein carbonyls, 3-nitrotyrosine
(3-NT), and protein-bound 4-hydroxy-2-trans nonenal (HNE), the
latter a highly reactive product of lipid peroxidation [9–11].
Protein carbonyls are introduced in the protein by various mecha-
nisms such as fragmentation of peptide backbone, abstraction of hydro-
gen atom at peptide alpha carbons, side chain oxidation (Lys, Arg, Pro,
Thr, etc.), and reaction of α- and β-unsaturated aldehydes with Lys or
His or Cys residues [8]. Protein carbonyls can also be introduced by sec-
ondary reactions of amino groups of lysine residues with reducing
sugars or their oxidation production (glycation/glycoxidation reac-
tions) [9,12]. Protein carbonyls are stable products of protein oxidation
and are determined by derivatization of the carbonyl group with 2,4-
dinitrophenylhydrazine (DNPH) followed by detection with immuno-
chemical or chromatography/mass spectrometry (MS) [10,13] .
3-nitrotyrosine (3-NT) is another type of protein modiﬁcation in-
duced by nitrosative stress. Nitrosative stress occurs due to increased
levels of reactive nitrogen species such as peroxynitrite, and nitric
oxide. Nitric oxide is produced as a byproduct during the conversion
of L-arginine to L-citrulline by the enzyme nitric oxide synthase
(NOS). Nitric oxide can react with superoxide to form a highly reac-
tive peroxynitrite. Peroxynitrite exist either as an anion (ONOO−)
or, peroxynitrous acid (ONOOH). The latter can undergo homolysis
to produce highly reactive hydroxyl radicals (OH•) and nitrogen
Fig. 1. Structure of curcumin (A), ferulic acid (B), and ferulic acid ethyl ester (C).
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soperoxyl intermediate and its homolytic cleavage. Nitrogen dioxide
can react with the tyrosyl free radicals to form 3-NT. 3-NT is detected
either immunochemically or by mass spectrometry (MS) [10,16,17].
Protein bound-HNE, is formed as result of reaction of the lipid per-
oxidation product (HNE) with cysteine (Cys), lysine (Lys), and histi-
dine (His) amino acids. Increased levels of free radicals can trigger
the process of lipid peroxidation by abstracting an allylic H atom
from the acyl chain of the α,β-unsaturated fatty acids in the lipid bi-
layer generating a carbon centered radical which can react with oxy-
gen to form peroxyl radicals. The peroxyl radical is capable of
abstracting an allylic H atom from adjacent allylic H atoms on acyl
chains of lipids forming a lipid hydroperoxide and C-centered radical,
thus propagating the chain reactions. Depending on the length of acyl
chain and degree of unsaturation the lipid hydroperoxide can pro-
duce highly reactive products such as acrolein, iso- and neuropros-
tanes, malondialdehyde, and HNE. Although other products of lipid
peroxidation are known, protein-bound HNE is the most commonly
studied marker to monitor lipid peroxidation. Protein-bound HNE is
detected either immunochemically or by mass spectrometry [10,18].
The products of oxidative modiﬁcation are cleared from the body
by protein degradation machinery such as the proteasome or certain
enzymes like carbonyl reductase can remove the modiﬁcations from
the proteins [19,20]. Several studies showed that oxidation or nitra-
tion of proteins affects their function and could play an important
role in the pathogenesis or progression of disease. The markers of ox-
idative/nitrosative stress were reported to be elevated in several neu-
rodegenerative diseases including AD, Parkinson disease,
amyotrophic lateral sclerosis, and Huntington disease or models
thereof [21–27]. Hence, developing a pharmacological approach to
combat oxidative stress could play a major role in reducing the risk
of diseases and promoting a healthy life. In an attempt to reduce the
side effects associated with allopathic medicine a number of studies
are now focusing on developing treatment regimen from naturally
occurring plant products. In this review the protective role of ferulic
acid (FA) and its derivative ferulic acid ethyl ester (FAEE) in neurode-
generation are summarized.
Natural plant products have gained enormous interest in the pre-
vention or treat of chronic diseases [28]. The antioxidant compounds
derived from natural products are commonly referred to as nutraceu-
ticals. Nutraceuticals have demonstrated neuroprotective activity in
either in vitro or in vivo models of a number of diseases including
cancer, ischemia, neurodegeneration etc. [29–32]. A large number of
compounds with antioxidant properties are found in natural prod-
ucts. These compounds are grouped into four main categories based
on their chemical structures: (i) ﬂavonoid polyphenols like epigallo-
catechin 3-gallate (EGCG) found in green tea and quercetin from ap-
ples, (ii) non-ﬂavonoid polyphenols such as resveratrol from grapes
and curcumin from tumeric, (iii) phenolic acids such as rosmarinic
acid from rosemary and sage, and (iv) organosulfur compounds
such as thiosulﬁnate allicin, from garlic. Most of the compounds
found in natural products have the ability to either scavenge free rad-
icals directly or indirectly by up regulation of endogenous cellular an-
tioxidant defense systems via upregulation of the transcription
factors such as nuclear factor erythroid-derived 2-related factor 2
(Nrf2) transcription factor that controls the expression of vitagenes,
such as heat shock proteins, thioredoxin, sirtuin, glutathione synthe-
sis and other proteins [33]. In Alzheimer's disease (AD) brain, the
levels of the vitagenes have been reported to be low, and might be
key player in the progression and pathogenesis of this devastating
disorder [34–36]. Hence an upregulation of vitagenes possibly may
play a role in preventing neurodegenerative diseases including AD
[37–39]. For example, as mentioned above, one of the products of
lipid peroxidation is HNE. HNE is highly reactive, it can react with
the lysine, histidine, and cysteine residues via Michael addition
which can induce a conformational change in the protein leading toaltered function of the proteins. One of the mechanisms by which
HNE is removed from the cell is via its conjugation to reduced gluta-
thione (GSH), this reaction is catalyzed by the enzyme glutathione
S-transferase (GST). Once the GS-HNE conjugate is formed it is
efﬂuxed out from the cell via efﬂux pumps such as multidrug resis-
tant protein (MRP1). However, in Alzheimer's disease (AD) both
GST and MRP1 proteins were found to be oxidatively modiﬁed
[35], which consequently led to decreased clearance of HNE from
the cell and aggravate cellular toxicity and eventually leading to
cell death and the appearance of the disease symptoms. A study by
Lui et al. [40] showed that HNE also can covalently modify the histi-
dine side chains of Aβ, leading to increased aggregation of this pep-
tide. The expression of GST is under the control of the Nrf2. Further,
the enzymes involved in the synthesis of GSH, a major endogenous
antioxidant, as mentioned above are also under the control of Nrf2.
Hence, up regulation of transcription factors like Nrf2 by natural an-
tioxidant compounds conceivably could protect the body against
cellular stress and consequently against the onset or progression of
the disease. As noted above, phytochemicals induces hormetic ac-
tion via speciﬁc signal pathways. One of such pathways involved
the up regulation of the transcription factor Nrf-2 which then
binds to antioxidant response element (ARE) and brings about the
expression of a number of vitagenes. Other mechanisms involve ac-
tivation of the sirtuin–FOXO pathway or transcription factors NF-κB
and CREB that leads to increased expression of antioxidant enzymes,
prosurvival proteins or growth factor, and anti-apoptotic proteins
[41–44]. One of the main concerns while using a crude preparation of
natural plant is that the extract of a plant may contain many active in-
gredients some of which may be beneﬁcial and some may not be good
for the kind of disease being treated; hence, precautions need to be
taken in dosage. Isolation of speciﬁc compounds from total plant ex-
tracts might help in preventing potential side effects. In this review,
the literature pertaining to ferulic acid (4-hydroxy-3-methoxycinnamic
acid) (FA) and its derivative ferulic acid ethyl ester (FAEE) in relation to
oxidative stress and neurodegeneration is summarized.
FA is found in a large number of fruits, some vegetables, and grains.
FA is synthesized in plants by the conversion of 4-hydroxycinnamic acid
to FA via caffeic acid. As can be seen in Fig. 1, FA has structural resem-
blance to curcumin. A number of preclinical studies showed that curcu-
min, a component of the Indian spice (tumeric), has antioxidant
properties [32,45]. FA has previously been shown from our laboratory
and others to have free radical scavenging activity toward hydroxyl
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protein [42,46,47]. The hydroxyl group in the FA can readily form a reso-
nance stabilized phenoxy radical and is key to its antioxidant property
[47–49]. FA can also protect biological membranes from lipid peroxida-
tion andneutralized peroxyl and alkoxyl radicals [50]. Because of it radical
scavenging property this compoundhas been included as an ingredient in
many skin lotions and sunscreens [51].
In our laboratory we showed that FA pretreatment protected pri-
mary neuronal cell cultures against hydroxyl- and peroxyl radical-
mediated oxidative damage [46]. Further, we also performed an in
vivo FA treatment to gerbils, followed by isolation of synaptosomes
and ex vivo treatment of isolated synaptosomes with hydroxyl and
peroxyl radicals. The results showed that FA is protective assessed
by the levels of protein carbonyls, HNE, and 3-NT [46]. Ferulic acid
(150 mg/kg i.p. for 4 days) protected the organ of Corti's neurons
from noise-induced oxidative stress damage in the guinea pig and
such a treatment reduced oxidative stress biomarkers HNE [52].
Mamiya et al. [53] showed that pretreatement with FA (5 mg/kg,
s.c.) once a day for 6 days improved cognitive function in mice treated
with buthionine sulfoximine (BSO), a selective inhibitor of γ-
glutamylcysteine synthetase, one of the key enzymes in glutathione
biosynthesis [54]. Further, they also showed that FA in addition to im-
proving memory also helped in reduction of the protein carbonyl
levels induced by BSO in these mice. In another study, the same
group [55] showed that pre-germinated brown rice prevents amyloid
beta-peptide-induced learning and memory impairment. However,
this group did not measure any oxidative stress markers in this Aβ
study. Further, studies from other laboratories showed the long-
term administration of FA protected mice against Aβ-induced learn-
ing and memory deﬁcits and cerebral ischemia [56,57]; however, in
this study oxidative stress markers were not determined. In a recent
study, Jagota and Rajadas showed the FA reduces the average length
of Aβ ﬁbrils in Caenorhabditis elegans (C. elegans) expressing human
Aβ intracellular in the body wall [58].
Inmultiple sclerosis, syncytin, a glycoprotein, is up regulated in glial
cells which induces the release of redox reactants, which are cytotoxic
to oligodendrocytes leading to acute demyelinating lesions. Syncytin
(S)-induced increase in protein carbonyls in the conditioned media of
HFAs (Hollow ﬁber assay) were reduced when HFAs were treated
with the antioxidant FA [59]. Ono et al. showed that FA can inhibit
both Abeta ﬁbril formation and also destabilizes pre-formed ﬁbrils in a
dose–dependent manner. However, so far no studies were conducted
to study the types of Aβ formed such as oligomer or monomers or di-
mers [60]. The recent literature suggests that the oligomeric form of
Aβ is highly toxic [61–63]. It will be interesting to knowhowFA can pre-
vent the formation of such species of Aβ. One speculation is that, FA pre-
vents the formation of oligomeric Aβ and thereby prevents the process
of lipid peroxidation, which is key to the process of triggering oxidative
stress by Abeta.
The ethyl ester derivative of FA (FAEE) (ethyl 4-hydroxy-3-
methoxycinnamate) has been shown to have both anti-inﬂammatory
and antioxidant properties as stated above for FA [42,46,64]. The pres-
ence of the ester group in FAEE makes this compound more lipophilic,
thereby increasing its ability to cross cell membranes, which are rich in
lipids. Especially in the case of brain the added lipophilicity of FAEE is
helpful in allowing a better transportation of FAEE across the blood
brain barrier. This property makes FAEE a better potential antioxidant
with respect to brain compared to FA [65]. Like FA, FAEE has also been
shown to scavenge hydroxyl and superoxide radicals [65]. In addition
to its ability to scavenge the free radicals directly, FAEE has also been
shown to up regulate protective genes such as heme oxygenase 1 (HO-
1) and HSP 70 [10,65]. In vivo administration of FAEE has been shown
to upregulate HO-1 expression not only in neurons but also in other
cell types as dermal ﬁbroblasts [66]. FAEE induction of HO-1 has been
shown to occur at both gene and protein levels suggesting that FAEE in-
duces a hormetic effect [65]. HO-1 is an antioxidant phase IIdetoxiﬁcation enzyme that degrades heme to carbon monoxide, iron
and biliverdin. Biliverdin is further converted to bilirubin, a potent anti-
oxidant, by the action of the enzyme biliverdin reductase (BVR). The
levels of HO-1 were found to be high in brains of subjects with AD and
MCI, the latter arguably the earliest form of AD, compared age-
matched controls [34,67,68]. In the AD brain, HO-1 protein is found in
neurons, astrocytes, choroid plexus epithelial cells, ependymocytes,
some vascular smooth muscle and endothelial cells [67,68]. HO-1 co-
localized with SP and NFT. Increased levels of HO-1 expression were
also documented and correlated with neuroﬁbrillary pathology in sub-
jects with MCI [69]. The observed increase of HO-1 in AD and MCI
could be a response to increased oxidative stress contributed in part by
increasing amount of amyloid, mitochondrial abnormalities, etc.
[70,71]. Further, our laboratory showed that the BVR levels were in-
creased in AD and MCI, however, the activity of BVR is decreased and
this decreased in activity due to oxidative and nitrosative modiﬁcation,
and altered phosphorylation of BVR [72,73]. Studies conducted so far
did not investigate the effect of FAEE on BVR activity or levels. However,
the mechanism by which HO-1 and HSP 70 are up regulated by FAEE is
not clearly understood. Since, heat shock protein expression is under
the control of Nrf-2, it is proposed to be one of the mechanisms by
which HO-1 and HSP70 are upregulated.
As mentioned above, FAEE also leads to decreased Abeta induced-
iNOS protein level in primary cell culture, and consequently de-
creased nitration and nitrosative stress in the cell [10]. The literature
on protein nitration in AD brain showed increased levels of markers
of protein nitration such as the lipid nitration product, 5-nitro-
gamma-tocopherol [74], dityrosine (DiTyr) and 3-NT [75]. Further,
immunohistochemical studies showed the presence of nitrated tau
in pre-tangles, tangles and tau inclusions in the AD brain [76]. In-
creased nitration is also evidenced in MCI brain suggesting that nitra-
tion is an important contributor in the progression and pathogenesis
of AD [77]. Hence, the use of naturally occurring compounds to combat
the oxidative and nitrosative stress could help in either preventing or
treating the progression of this devastating disorder [17].
In our laboratory we showed that FAEE can protect against amy-
loid beta-peptide-induced oxidative stress and loss of phospholipid
asymmetry [78]. Recent studies showed that the oligomeric form of
amyloid beta-peptide can insert itself in the phospholipid bilayer
thereby initiating the process of lipid peroxidation and consequently
in the loss of phospholipid asymmetry [79,80]. The loss of phospho-
lipid asymmetry has been reported in AD, familial AD (FAD) brain
[81], and in the brain from APPNLh/APPNLh×PS-1P264L/PS-1P24L
human double mutant knock-in mice, an amyloid model of AD
[78,82,83]. In a cell it is important to maintain the phospholipid
asymmetry, since exposure of the aminophospholipid phosphatidyl-
serine (PtdSer) to the outer leaﬂet signals the initiation of an apopto-
tic process [81,84]. In addition to loss of PtdSer asymmetry, the
process of lipid peroxidation may also disrupt phosphatidylinositol-
4,5-bisphosphate metabolism [79], thereby altering the dielectric
structure [80], and increases bilayer permeability [85] consequently
leading to altered cellular function and cell death.
A safer dose needs to be determined for the nutraceuticals such as
FA [10,56]. There are instances when a compound could augment the
generation of free radicals and consequently may play a role in oxida-
tive stress and disease perse. For example, vitamin C is a pro-oxidant.
It can convert ferric ions (Fe3+) and cupric ions (Cu2+) to ferrous
(Fe2+) and cuprous (Cu+) ions, respectively, resulting in the forma-
tion of ROS. Vitamin C supplementation has been shown to increase
DNA damage in the lymphocytes of healthy volunteers [86].
In conclusion, we live in an environment where we are continu-
ously challenged by various sort of stresses. These cellular stresses
lead to altered cellular functions which may contribute to the onset
of various diseases including neurodegenerative disease, cardiovascu-
lar disease, stroke, cancer, etc. The naturally occurring plant products
consist of a variety of molecules, and only some of these chemicals are
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are present at high levels which can induce the expression of phase
II enzymes [87]; and resveratrol (a chemical found in the skin of red
grapes and wine) can activate stress response pathways [88]. However,
at high concentrations these phytochemicals have been shown to have
cytotoxic effects [89]. As noted above, most of the phytochemicals
works via hormetic mechanisms of action.
The use of nutraceuticals and the understanding the mechanism of
their action could be beneﬁcial to prevent or delay the onset of a disease.
Studies are in progress in our laboratory to further delineate the mecha-
nism of action for FAEE and its use in diseases involving oxidative stress.
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